Quthero Revenue and Competitors
Estimated Revenue & Valuation
- Quthero's estimated annual revenue is currently $1.4M per year.
- Quthero's estimated revenue per employee is $140,000
Employee Data
- Quthero has 10 Employees.
- Quthero grew their employee count by 67% last year.
Quthero's People
Name | Title | Email/Phone |
---|---|---|
1 | Founder | Reveal Email/Phone |
2 | Chief Business Officer | Reveal Email/Phone |
3 | COO, CFO | Reveal Email/Phone |
4 | Research Scientist | Reveal Email/Phone |
5 | Business Development Lead/Medical Science Liaison | Reveal Email/Phone |
6 | Senior Scientist | Reveal Email/Phone |
Quthero Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $3.5M | 31 | 15% | N/A | N/A |
#2 | $15M | 596 | 16% | N/A | N/A |
#3 | $5.5M | 39 | -2% | N/A | N/A |
#4 | $3.6M | 26 | 0% | N/A | N/A |
#5 | $3.5M | 39 | 34% | N/A | N/A |
#6 | $3.5M | 25 | 25% | N/A | N/A |
#7 | $3.4M | 24 | 4% | N/A | N/A |
#8 | $35M | 156 | 10% | N/A | N/A |
#9 | $35M | 245 | -10% | N/A | N/A |
#10 | $35M | 134 | -9% | $472M | N/A |
What Is Quthero?
Quthero is a privately held company advancing regenerative therapies based on its proprietary Q-peptide technology for applications in dermatology and cardiology. Q-peptide is a synthetic, bioactive, peptide sequence derived from Angiopoietin-1, with documented regenerative and anti-inflammatory properties. Q-peptide platform enables versatile applications in areas where cell survival, anti-inflammatory effects, and regenerative support are critical. Quthero’s pipeline focuses on applications of post-aesthetic procedures, wound healing and regeneration, and cardiovascular health.
keywords:N/AN/A
Total Funding
10
Number of Employees
$1.4M
Revenue (est)
67%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2M | 10 | 0% | N/A |
#2 | $1M | 12 | N/A | N/A |
#3 | $1.4M | 16 | N/A | N/A |
#4 | $2.3M | 22 | -12% | N/A |
#5 | $1.8M | 22 | -4% | N/A |